Dataset from An Open-Label, Dose-Escalation, Phase 1 Study Evaluating the Safety and Tolerability of Weekly Dosing of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and Refractory Multiple Myeloma

The primary objective of this study is to determine the safety profile, tolerability, and maximum tolerated dose of ixazomib citrate (MLN9708) when taken orally on a weekly dosing schedule by patients with relapsed and refractory multiple myeloma (RRMM). Secondary objectives include pharmacokinetics and response rates.

本研究的主要目的为明确枸橼酸伊沙佐米（ixazomib citrate，MLN9708）采用每周口服给药方案时，在复发难治性多发性骨髓瘤（relapsed and refractory multiple myeloma，RRMM）患者中的安全性特征、耐受性及最大耐受剂量。次要研究目的包括药代动力学特征与应答率。